News

Alkeus Pharmaceuticals Announces Data Presentations at the American Academy of Ophthalmology (AAO) 2024 Annual Meeting, October 18-21 in Chicago

Alkeus Pharmaceuticals Announces Results from the SAGA Study of Oral Gildeuretinol in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

Alkeus Pharmaceuticals Announces Presentation of a TEASE-3 Study Update Showing Progression Stalled in Early-Stage Stargardt Disease Patients Treated with Gildeuretinol

Alkeus Pharmaceuticals Appoints Tamara Dillon as Chief Human Resources Officer

Accomplished Biotech Leader Michel Dahan Joins Alkeus as President and CEO

Alkeus Pharmaceuticals Appoints Eric L. Trachtenberg as Chief Legal Officer

Alkeus Pharmaceuticals Announces Positive Interim Results Demonstrating No Signs of Disease Progression in Early-Stage Stargardt Disease Patients Treated with Gildeuretinol

Alkeus Pharmaceuticals Announces Presentation of Positive Gildeuretinol Data in Early-Stage Stargardt Disease Patients During the ARVO 2024 Annual Meeting May 5-9